UPDATE 1-Novartis faces fresh blow to pipeline with del-desiran drug setback

(Recasts with context, details, share price indication) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said its experimental drug for a muscle wasting disorder failed in a late-stage

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)